🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Comparison Between Bipolar Transurethral Resection of the Prostate and Moses Assisted Holmium Laser Enucleation of the Prostate

RecruitingNAAges any - anyMaleFundacio Puigvert
NCT06649357 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Introduction: Multiple studies have demonstrated the superiority of HoLEP in aspects such as transfusión rates or postoperative stay. On the other hand, no differences have been observed in terms of functional outcomes between both techniques, and surgical times reported in different studies tend to be longer for HoLEP. These results likely contribute to TURP, especially with bipolar energy (Bi-TURP), continuing to be considered by many the gold standard for surgical treatment of BPH. Sofware and hardware upgrades to the Lumenis Pulse 120H. system in 2017, delivered MOSES 2.0, a single-use laser fibre used to perform MOSES augmented HoLEP (MoLEP). MoLEP has shown to be superior in intraoperative outcomes when compared to traditional HoLEP. The availability of new morcellators might also decrease surgical time for HoLEP. This changing landscape for BPH endoscopic surgery deserves a re-ev

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with maximum flow rate \< 15 ml/sec before obstructive surgery or with maximum flow rate \> 15 ml/sec and urodynamic study showing high-flow obstruction defined as bladder outlet obstruction index \> 40. * Patients with moderate to severe lower urinary tract symptoms (LUTS) according to the International Prostate Symptom Score (IPSS). Score between 8 and 35. * Patients with a prostate volume between 40 and 80 cc, measured by urological ultrasound or MRI. Exclusion Criteria: * History of prior prostatic obstructive or urethral surgery. * Diagnosis of prostate neoplasia. * Diagnosis of urothelial neoplasia. * Lack of flowmetry or IPSS data before surgery. * Diagnosis or suspicion of hypo/acontractile detrusor before prostatic obstructive surgery. * Diagnosis or suspicion of neurogenic bladder or neurological disease. * History of pelvic radiation therapy.
💊

What it tests

  • MoLEP
  • BiTURP
📍

Where

6 sites
Complejo Hospitalario Universitario de Santiago de Compostela
Santiago de Compostela, Spain
Fundacio Puigvert
Barcelona, Spain
Hospital Univesitari de Bellvitge
L'Hospitalet de Llobregat, Spain
Hospital Universitario Marqués de Valdecillas
Santander, Spain
Hospital Universitario de Cabueñes
Gijón, Spain
Hospital Universitario Río Hortega
Valladolid, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy